| n | Univariable analysis HR (95% CI)a | p value | Multivariable analysis HR (95% CI)a | p value |
---|---|---|---|---|---|
Menopausal status | |||||
 Pre- | 360 | 1.365 (0.958–1.985) | 0.086 |  |  |
 Post- | 703 | 1.00 |  |  |  |
Tumor size | |||||
 ≤ 2.0 cm | 639 | 1.00 | < 0.0001 | 1.00 | < 0.0001 |
 > 2 cm | 426 | 2.964 (2.135–4.157) |  | 2.410 (1.645–3.575) |  |
Lymph node metastasis | |||||
 Negative | 743 | 1.00 | < 0.0001 | 1.00 | < 0.0001 |
 Positive | 317 | 2.990 (2.160–4.154) |  | 2.568 (1.742–3.800) |  |
Tumor grade | |||||
 1 | 561 | 1.00 | 0.0003 | 1.00 | 0.014 |
 2+3 | 479 | 1.859 (1.331–2.624) |  | 1.627 (1.101–2.420) |  |
Estrogen receptor status | |||||
 Positive | 853 | 1.00 | < 0.0001 | 1.00 | 0.024 |
 Negative | 223 | 2.089 (1.471–2.925) |  | 1.964 (1.094–3.610) |  |
Progesterone receptor status | |||||
 Positive | 735 | 1.00 | < 0.0001 | 1.00 | 0.843 |
 Negative | 336 | 1.946 (1.406–2.681) |  | 1.054 (0.614–1.736) |  |
HER2 status | |||||
 Negative | 897 | 1.00 |  | 0.186 |  |
 Positive | 162 | 1.345 (0.861–2.022) |  |  |  |
Chemotherapy | |||||
 No | 512 | 1.00 | 0.0221 | 1.00 | 0.0021 |
 Yes | 512 | 1.480 (1.107–2.201) |  | 0.509 (0.335–0.780) |  |
CEA levelb | |||||
 Low | 885 | 1.00 | < 0.0001 | 1.00 | 0.047 |
 High | 191 | 2.415 (1.057–2.091) |  | 1.520 (1.005–2.245) |  |
CA15-3 levelc | |||||
 Low | 762 | 1.00 | < 0.0001 | 1.00 | < 0.0001 |
 High | 314 | 2.824 (2.050–3.887) |  | 2.088 (1.457–2.901) |  |